$3.5M
+$3.5M this year1 filing since 2026 · latest Equity filed
Neosoma is a medical technology company in Groton, Massachusetts that builds AI software for neuro-oncology imaging. Its cloud platform analyzes brain MRI scans to segment tumors at voxel-level precision, compute volumetric tumor burden, generate contours for radiation treatment planning, and track lesions longitudinally across timepoints. The company holds FDA 510(k) clearances for Neosoma HGG (high-grade glioma, cleared 2022) and Neosoma Brain Mets (brain metastases, cleared December 2025). The platform is SOC 2 Type II certified and HIPAA compliant, and is used at clinical sites including UCLA, UF Health, JFK Hackensack and Methodist Health System.
What sets it apart
FDA-cleared, fully automated 3D tumor segmentation and longitudinal tracking for brain cancer, replacing manual radiologist measurement and feeding contours directly into radiation treatment planning systems, with Category 3 CPT codes available for reimbursement.
A cloud-based, FDA-cleared AI platform that ingests brain MRI studies and automatically maps, contours, quantifies and tracks tumor lesions for multidisciplinary neuro-oncology teams.
